Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PDPN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PDPN ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native O-glycosylation. |
View PDPN Products |
| Gene Delivery | PDPN Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based conformation assays. |
View PDPN Products |
| Benchmark Ab | Anti-PDPN (Sequence of NZ-1 / hgMPM-1) Recombinant positive control for binding and internalization assays. |
View PDPN Products |
| Validator | PDPN siRNA Set For knockdown verification and specificity controls in functional assays. |
View PDPN Products |
| Related Target A | CLEC1B (CLEC-2) Primary physiological ligand of PDPN; critical for platelet aggregation and metastasis assays. |
View CLEC1B Products |
| Related Target B | CD3E (CD3 epsilon) Essential TCR subunit for developing PDPN-targeted bispecific T-cell engagers (BiTEs). |
View CD3E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-Dependent Epitope Binding | HEK293 host expression ensures native human O-glycosylation (PLAG domain preservation). |
| On-Target, Off-Tumor Toxicity Screening | Truncated ECD variants and mutant panels strictly verified by mass spectrometry and sequence analysis. |
| Lack of Benchmarking Controls | Clinical-grade recombinant Benchmark Antibodies (Biosimilars) available. |
| Conformational Cell-Based Assays | Lentivirus Premade Particles for stable, high-expression cell line generation (no VLP instability). |
Live PDPN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDPN therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs), CAR-T therapies, and bispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific glycoforms (such as those identified by CasMab technology) to minimize on-target, off-tumor toxicities in normal tissues like lymphatic endothelium and pulmonary alveoli.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Academic Institutions, Biotech Startups | Glioblastoma, Mesothelioma, Squamous Cell Carcinoma | Internalization Assay (Need high-purity, natively glycosylated ECD-Fc) |
| CAR-T / Cell Therapy | Nagoya University, Clinical Consortia | Solid Tumors, Brain Metastases | Target Density & Specificity Validation (Need stable cell lines via Lentivirus) |
| Bispecific Antibody | Biopharma Innovators | Malignant Pleural Mesothelioma | Heterodimer Validation & T-cell activation (Need CD3E and PDPN proteins) |